表紙:避妊薬の世界市場-2023年~2030年
市場調査レポート
商品コード
1319158

避妊薬の世界市場-2023年~2030年

Global Contraceptive Drugs Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.16円
避妊薬の世界市場-2023年~2030年
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の避妊薬市場は2022年に136億米ドルに達し、2030年には224億米ドルに達するなど、有利な成長が予測されています。世界の避妊薬市場は、予測期間中(2023~2030年)にCAGR 6.6%を示すと予測されています。

避妊薬の使用は、望まない妊娠を避けることで中絶の必要性を最小限に抑えます。その結果、世界的に妊産婦死亡の主な原因の一つである危険な中絶の発生を最小限に抑えることができます。避妊は、母体死亡率と乳児死亡率を下げる上で極めて重要です。妊娠が計画的に行われ、適切な間隔があけば、女性は適切な出産前ケアを受けることができ、女性の健康と新生児の健康状態を改善することができます。

世界の避妊薬市場は、家族計画や望まない妊娠を防ぐ必要性への注目が高まっていること、若い女性における避妊使用の増加、教育水準の向上が市場の成長を後押ししていることなど、さまざまな要因によって牽引されています。

市場力学

人口の意識の高まりと望まない妊娠を防ぐための政府の取り組みの増加

世界人口の増加、特に新興経済諸国では、望まない妊娠、中絶のリスク、性的障害に対する懸念が高まっています。こうしたリスクを減らすために、政府の取り組みが推進されています。インドは2020年までに、新たに4,800万人の利用者に家族計画サービスを提供することを約束し、米国は避妊の普及と望まない妊娠の減少を目指し、母子保健イニシアチブを設立しました。

世界中で増加する望まない妊娠の割合

世界中で望まない妊娠の割合が増加していることは、人々の間で大きな懸念となっています。米国疾病予防管理センター(CDC)によると、米国では年間610万件の妊娠のうち45%が望まない妊娠です。したがって、意図しない妊娠の割合の増加は、予測期間を通じて市場の成長に拍車をかけると思われます。

例えば、2019年時点のwho updated factsheets 2023によると、低・中所得国(LMICs)の15~19歳の青少年の年間妊娠数は推定2,100万件で、50%が望まない妊娠であり、1,200万件が出生しています。望まない妊娠の55%は中絶に至りますが、LMICにおいて多くは安全ではありません。

思春期の母親は、20~24歳の女性と比較して子癇、産褥性子宮内膜炎、全身感染症のリスクが高いです。10~14歳の女児の思春期出産率は増加しており、サハラ以南のアフリカとラテンアメリカ・カリブ海諸国ではより高いです。

避妊に対する意識の欠如

避妊に関する認識不足とは、人々、集団、文化が、その利用可能性、使用方法、有効性、考えられる利点など、さまざまな避妊方法について十分な理解をしていない、あるいは不十分な状態を指します。意図しない妊娠、性感染症(STI)の蔓延、その他の健康上の合併症は、理解不足から生じる可能性があります。

COVID-19の影響分析

COVID-19は避妊薬市場の価値に大きな影響を与えています。パンデミックの間、避妊の開始と維持における遠隔医療や遠隔医療の利用など、革新的な技術や手法の利用が標準的な治療となっています。数多くの遠隔医療法により、個人はテクノロジーを介して医療提供者とつながることができます。医療従事者が少ない場所で幅広い選択肢の避妊具を配布する移動支援プログラムを支援することが、この産業の価値を高めています。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、普及率が低く、この地域に主要な市場プレーヤーがいないことから、世界の避妊具に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の避妊薬市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究開発活動の増加
      • 性感染症(STD)の流行と好意的な取り組み
    • 抑制要因
      • 避妊薬に伴う副作用
    • 機会
      • 組織による取り組みの増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 経口避妊薬
  • 局所避妊パッチ
  • 避妊注射剤

第8章 流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Church & Dwight Co Inc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Teva Pharmaceuticals
  • Merck & Co Inc
  • Agile Therapeutics
  • Ansell Ltd
  • Mayer Laboratories Inc
  • Veru Inc,
  • Pfizer Inc
  • Bayer AG,
  • Abbvie Inc

第12章 付録

目次
Product Code: PH6608

Market Overview

The global contraceptives drugs market reached US$ 13.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 22.4 billion by 2030. The global contraceptives drugs market is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030).

Contraception usage minimises the need for abortion by avoiding undesired pregnancies. As a result, it minimises incidences of unsafe abortion, which is one of the main causes of maternal mortality globally. Contraception is critical in lowering mother and infant mortality rates. When pregnancies are planned and spaced adequately, women may get adequate prenatal care, improving their health and the health outcomes for their newborns.

The global contraceptive drugs market is driven by various factors such as the growth in focus on the need for family planning and preventing unwanted pregnancy, the increase in the use of contraception in young women along with the rise in higher educational attainment propels the market growth.

Market Dynamics

Rising Awareness Among Population & Increasing Government Initiatives to Prevent Unwanted Pregnancies

The global population's increasing growth, particularly in developing economies, raises concerns about unwanted pregnancies, abortion risks, and sexual disorders. Government initiatives are being driven to reduce these risks. India committed to providing family planning services to 48 million new users by 2020, while the U.S. established a maternal and infant health initiative to promote contraception use and reduce unwanted pregnancy rates.

Increasing Rate of Unwanted Pregnancies across the Globe

The growing rate of unwanted pregnancies worldwide is a major concern among the population. As per the Centers for Disease Control and Prevention (CDC), 45% of the 6.1 million annual pregnancies in the U.S. are unwanted. Hence, the increasing rate of unintended pregnancies will spur the market growth across the forecast period.

For instance according to who updated factsheets 2023 as of 2019, adolescents aged 15-19 in low- and middle-income countries (LMICs) had an estimated 21 million pregnancies annually, with 50% unintended and 12 million births. 55% of unintended pregnancies result in abortions, which are often unsafe in LMICs.

Adolescent mothers face higher risks of eclampsia, puerperal endometritis, and systemic infections compared to women aged 20-24. Adolescent birth rates for girls aged 10-14 are increasing, with higher rates in sub-Saharan Africa and Latin America and the Caribbean.

Lack of Awareness About Contraception

A lack of awareness regarding contraceptives refers to a condition in which people, groups, or cultures have inadequate or insufficient understanding about various methods of contraception, including its availability, usage, efficacy, and possible advantages. Unintended pregnancies, the spread of sexually transmitted diseases (STIs), and other health complications can result from a lack of understanding.

COVID-19 Impact Analysis

COVID-19 has had a substantial influence on the value of the contraceptive market. During the pandemic, the use of innovative techniques and technology, including as the use of telemedicine and telehealth in contraceptive start and maintenance, became the standard of care. Numerous telehealth methods allow individuals to connect with health care providers via technology. Supporting mobile outreach programmes that distribute a wide choice of contraceptive products in locations where healthcare practitioners are few has boosted the industry's value.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global contraceptives owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global contraceptive drugs market growth over the forecast period.

Segment Analysis

The global contraceptive drugs market is segmented based on type , distribution channel and region.

Oral Contraceptive Pills From By Type Segment Accounted for Approximately 46.3% of the Contraceptives Drugs Market Share

The oral contraceptive pills from by type segment with around 46.3% is expected to dominate during the forecast period. Mechanism of action inovled in oral contraceptive pills is progesterone which is primarily responsible for preventing pregnancy. The main mechanism of action is the prevention of ovulation; they inhibit follicular development and prevent ovulation.

For instance, in Nov 2022, Lupin received FDA clearance to distribute Drospirenone tablets, a generic oral contraceptive pill, in the United States. The FDA has provisionally accepted Drospirenone Tablets' 4 mg strength abbreviated new drug application (ANDA).

Geographical Analysis

North America Accounted for Approximately 37.6% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

North America is estimated to hold about 37.6% of the total market share throughout the forecast period because of favourable FDA approvals, government programmes, a high number of undesired pregnancies, an increase in the frequency of sexually transmitted infections, and other factors.The US government has undertaken various family planning and contraceptive education initiatives, which have increased the sector's income. There are numerous unplanned pregnancies in the United States.

For instance In Oct 2022,Dare Bioscience, a leader in women's health innovation, has been granted an Investigational Device Exemption (IDE) by the FDA to conduct a single-arm, open-label pivotal contraceptive efficacy study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive. The FDA determined that the company provided sufficient data to support the study, including the results of the postcoital test (PCT) clinical study. PCT clinical trials have been used as a surrogate marker for contraceptive effectiveness.

Competitive Landscape

The major global players in the contraceptives drugs include: Church & Dwight Co Inc, Teva Pharmaceuticals, Merck & Co Inc, Agile Therapeutics, Ansell Ltd, Mayer Laboratories Inc, Veru Inc, Pfizer Inc, Bayer AG, Abbvie Inc and others.

Why Purchase the Report?

  • To visualize the global contraceptives drugs market segmentation based on type, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of contraceptives drugs market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global contraceptives drugs report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Distribution Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase R&D Activities
      • 4.1.1.2. Rising Prevalence Of Sexually Transmitted Diseases (STD) Coupled With Favourable Initiatives
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated With Contraceptives Pills
    • 4.1.3. Opportunity
      • 4.1.3.1. Increase in Initiatives by Organizations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post Covid-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Oral Contraceptive Pills *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Topical Contraceptive Patch
  • 7.4. Contraceptive Injectables

8. By Distribution Channel

  • 8.1. Introduction
      • 8.1.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
      • 8.1.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Spain
      • 9.3.5.5. Italy
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1.1. Church & Dwight Co Inc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Teva Pharmaceuticals
  • 11.3. Merck & Co Inc
  • 11.4. Agile Therapeutics
  • 11.5. Ansell Ltd
  • 11.6. Mayer Laboratories Inc
  • 11.7. Veru Inc,
  • 11.8. Pfizer Inc
  • 11.9. Bayer AG,
  • 11.10. Abbvie Inc
  • LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us